Last reviewed 2026-04-19 · How we verify
Home › Drugs › TransThera Sciences (Nanjing), Inc. › Combination Product: Nab-Paclitaxel Combination Product: Nab-Paclitaxel
At a glance
Generic name Combination Product: Nab-Paclitaxel Sponsor TransThera Sciences (Nanjing), Inc. Modality Small molecule Phase Phase 1
Approved indications
No approved indications tracked.
Common side effects
No common side effects on file.
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
Drug Landscape https://druglandscape.com/drug/combination-product-nab-paclitaxel · Machine-readable: markdown · JSON · Editorial policy: /editorial-policy
Not medical advice. Information on this page is collated from primary regulatory and clinical-trial sources for research purposes. It is not a substitute for consultation with a licensed healthcare professional. See our editorial policy for sourcing and methodology.